日期: 2025 年 7 月 16 日

SHENZHEN, CHINA, July 16, 2025 – (ACN Newswire) – On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy. At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast Asia and the Middle East. This move not only facilitates CMS’s comprehensive and sustainable development in Asia-Pacific markets, but also enhances our international influence and competitiveness, enabling us to serve broader patient populations with high-quality and affordable medication options.”         New CMS New Ascent Over the 33-year journey, CMS has continuously challenged and surpassed itself through three strategic transformations to adapt to the external ecosystem: evolving from “China’s largest CSO” (1992-2010), to “transition from CSO to Pharma” (2010-2018), and since 2018, gradually establishing three core strategies of “Innovation-driven, Specialty Breakthroughs and Industrial Internationalization” to promote the upgrading and iteration of “New CMS”, accumulating momentum for takeoff. CMS has established a comprehensive pharmaceutical product lifecycle management system, covering every stage from target identification to clinical development, product registration and commercialization. The Group focuses on FIC (First-in-Class) and BIC (Best-in-Class) innovative products, and has meticulously built a pipeline of approximately 40 innovative products with differentiated advantages, among which 5 innovative drugs have been approved and successfully commercialized in China. With the impact of VBP (Volume-Based Procurement) mostly cleared, CMS has entered a new cycle of high-quality and sustainable development driven by exclusive and innovative drugs. In specialty fields, the Group focuses on cardio-cerebrovascular, gastroenterology, ophthalmology and skin health, continuously deepening product portfolios and expert networks. Notably, the Group’s skin health business “DERMAVON” has emerged as a leader in its sector and is proposed for an independent listing on the Main Board of the Hong Kong Stock Exchange. A Pioneer in Industrial Internationalization Synergized Development Across the Entire “R&D, Manufacturing and Commercialization” Value Chain Since 2022, CMS has initiated its “Industrial Internationalization” strategy by extending the Group’s advantages and resources from the Chinese market to emerging markets. Utilizing Singapore as the strategic pivot, the Group has established a localized cluster comprising CMS R&D, PharmaGend, and Rxilient, achieving synergized development across the entire pharmaceutical value chain from R&D to production and commercialization, driving deeper and broader market expansion across the Asia-Pacific region. Internationalization of the Commercialization System: Rxilient serves as a platform for drug introduction, R&D and commercialization, operated by a professional and experienced localized team. Headquartered in Singapore, its business has expanded to 14 countries and regions including Malaysia, Thailand, Vietnam, the Philippines, Indonesia, and the Middle East, helping partners from China, the US, and Europe bring innovative drugs to emerging markets while introducing more high-quality and affordable treatment options to local markets. As of now, Rxilient has cumulatively submitted marketing applications for nearly 20 drugs and medical devices across Southeast Asia, the Middle East, Hong Kong, Macao and Taiwan, covering therapeutic areas such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Internationalization of the Production System: PharmaGend, as an international CDMO platform based in Singapore, has a site spanning 30,000 square meters and is capable of manufacturing dosage forms such as tablets and capsules, with plans to expand production lines for injections, ointments, and nasal sprays. The factory has been certified by international authorities such as the FDA and the HSA, demonstrating its high-standard pharmaceutical manufacturing capabilities for global export . Structural factors including large population bases, healthcare insurance expansion and rising chronic disease burdens are transforming Southeast Asia, the Middle East and other emerging markets into new growth engines for the global pharmaceutical industry. Leveraging its integrated ecosystem, CMS is forming a novel model for Chinese pharmaceutical globalization – not only enabling incremental market conversion for its own products in emerging markets, but also providing global partners with a reliable one-stop solution, thereby generating additional growth momentum for the Group. Looking ahead, CMS will continue advancing its three core strategies to build the long-term value system of “New CMS”. By persistently enhancing accessibility to pharmaceutical innovation, CMS aims to benefit more patients, achieve sustainable healthy development, and deliver substantial value returns to investors. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

Kuala Lumpur, Malaysia – July 16, 2025 – (SeaPRwire) – maxWin Sports (https://maxwinofficial.com) today joins EBM-GIGA Racing Team as a Brand Partner and will be making the company’s motorsports debut in the Malaysian round of the AUTOBACS SUPER GT series held at the Petronas Sepang International Circuit. The sponsorship will also include selected rounds in the GT World Challenge Asia series. EBM-GIGA Racing Team will be spearheaded by Malaysian veteran racer Adrian D’Silva who will team up alongside Frenchman Dorian Boccolacci driving a Porsche 911 GT3R (992) in the GT300 Class this weekend. “Our Brand Partnership underlines maxWin Sports’ “Beyond Limits” which is an initiative to champion local Malaysian athletes,” said maxWin Sports’ Chief Executive Officer James Stapleton. “The goal is to empower Malaysian sports, to support Malaysia’s growing sports ecosystem and to make an impact in the local sports industry. We are aiming at inspiring the next generation of athletes in Malaysia. This aligns with maxWin’s broader mission of giving back to the community and fostering excellence beyond the digital space.” The 59-year-old D’Silva has 146 race starts to his credit and will be making his first appearance in SUPER GT. D’Silva’s career highlights include multiple appearances in the Asian Le Mans series and GT World Challenge Asia since 2010, and the Porsche Carrera Cup Asia, where he currently competes driving for Earl Bamber Motorsport. In 2021, he participated in the Spa-Francorchamps 24-Hour race with EBM Giga Racing, a 100 percent Malaysian-owned team. His achievements include a 3rd place finish at the Sepang 12 Hours in 2023, 4th in LMP3 at Asian Le Mans 2016, 4th in 2013 and 5th in 2014 at the Merdeka Endurance Race, and 3rd in the Asian Touring Car Series in 2009. Boccolacci meanwhile, joins the team with 239 race starts. Having successfully competed in a number of single-seater categories, winning races in GP3 and competing in FIA Formula 2 among other things, Boccolacci garnered success in GT cars, winning the V6 class at the 2020 24 Hours of Nurburgring and becoming the 2023 champion of the Porsche Carrera Cup France. The Autobacs SUPER GT returns to Malaysia after an absence of 12 years and will be staged for three years following the signing of an agreement between HARO Sports & Entertainment as the rights holder and promoter for the Malaysian round of the SUPER GT and the GT Association (GTA) as the rights holders for SUPER GT. The Malaysian round of the 2025 Autobacs SUPER GT race will be run over a distance of 300km and will be the third round of the 2025 race calendar which features a total of eight rounds – seven of which will take place in various circuits within Japan. Malaysia will remain as the ONLY overseas race for Super GT. The weekend concluded on a high note, with the EBM-GIGA Racing Team receiving the Best Team Performance Award, a recognition of their outstanding teamwork and competitive spirit throughout the event. About maxWin maxWin is one of the most trusted online casinos in Malaysia, holding authorization and licenses to operate in various countries such as Malaysia, Vietnam, Indonesia, Thailand, Cambodia, the Philippines, India, and Korea. As a Malaysia online casino featured among the best online casinos in Asia for 2024, we are recognized as one of the premier online casinos. About SUPER GT SUPER GT features the top manufacturers and drivers from Japan competing in the GT500 and GT300 Classes, attracting the best of Japanese manufacturers the likes of Nissan, Lexus, Toyota, Honda and Subaru, as well as continental marques that include Aston Martin, Lamborghini, Mercedes-Benz, Ferrari and BMW. Social Links Facebook: https://www.facebook.com/maXwin.Official88/ Instagram: https://www.instagram.com/maxwin.my/ YouTube: https://www.youtube.com/@maXwinofficial-88 Website: https://maxwinofficial.com